FDA Launches READI-Home Challenge for Home Medical Devices

April 13, 2026

The FDA READI-Home Challenge: A New Initiative to Reduce Readmissions

Ari Markenson Venable LLP + Follow Contact LinkedIn Facebook X Send Embed

On April 7, 2026, the U.S. Food and Drug Administration (FDA), through its Center for Devices and Radiological Health (CDRH), launched the READI-Home (Reducing Readmissions through Device Innovation in the Home) Innovation Challenge as part of its broader "Home as a Health Care Hub" initiative. The program is designed to accelerate the development of medical devices that enable safe, effective care in the home and reduce avoidable hospital readmissions.

Hospital readmissions are a significant cost and quality challenge, particularly for those with multiple chronic conditions. An aging population, a rising chronic disease burden, provider shortages, and increasing healthcare costs are driving a shift toward decentralized, patient-centered care models.

The FDA's initiative is designed for a strategic pivot to position the home as a core site of care delivery, supported by connected, user-friendly medical technologies. The READI-Home challenge seeks to:

• Identify and accelerate innovative medical devices that support recovery after hospital discharge
• Reduce preventable readmissions by improving monitoring, adherence, and early intervention in the home
• Empower patients and caregivers with technologies designed for non-clinical settings and
• Advance health equity by enabling access to care outside traditional healthcare facilities The initiative prioritizes solutions that address unmet clinical needs and are usable by patients or lay caregivers in real-world home environments. The challenge is structured in two phases:

1. Submission and Selection Phase (April - September 2026). Applicants submit proposals through the FDA's Q-submission process. Submissions must include device descriptions, feasibility evidence, and a data development plan
2. FDA Collaboration ("Sprint") Phase (Beginning December 2026). Up to nine selected participants engage in intensive collaboration with FDA experts. Participants receive iterative feedback on device design, testing, and regulatory strategy According to the FDA, the READI-Home challenge offers early and frequent interaction with FDA reviewers.

Note: Participation does not constitute premarket approval but is intended to streamline future regulatory review.

Additionally, the READI-Home challenge builds on the FDA's broader "Home as a Health Care Hub" framework, which is intended to reimagine the home as an integrated extension of the healthcare system. This includes efforts to design interoperable, patient-centered device ecosystems and to address barriers such as usability, access, and data integration.

With this challenge, the FDA is signaling strong support for home-based medical device innovation as a tool to reduce costs and improve outcomes. The READI-Home Innovation Challenge represents a targeted FDA effort to catalyze next-generation medical devices that shift care into the home. By combining regulatory engagement with innovation incentives, the program is intended to reduce hospital readmissions while advancing a more decentralized, patient-centric healthcare system.

Interested device innovators can achieve early engagement with FDA through structured programs like READI-Home that may provide a strategic regulatory advantage. Companies developing remote monitoring, AI-enabled diagnostics, or caregiver-operated devices may find significant opportunities in this space. Solutions that demonstrate clear impact on readmissions and usability in non-clinical settings will be best positioned for selection.

As with any product going through FDA approval, it is important to contemporaneously develop a commercial launch plan that includes a coverage and reimbursement strategy for Medicare, Medicaid, and commercial insurance.

Send Print Report

Latest Posts

• Inside the Ad Law Tool Kit: Advertising Claim Substantiation
• The FDA READI-Home Challenge: A New Initiative to Reduce Readmissions
• Intuit v. FTC Reshapes Deceptive Advertising Enforcement Authority
• FTC OkCupid Settlement: Deceptive Data Sharing, Privacy Policy Compliance, and Section 5 Takeaways
• Athletes and Political Speech: The Legal Landscape and Considerations for Employers See more »

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
Attorney Advertising.

©
Venable LLP

Written by:

Venable LLP Contact + Follow Ari Markenson + Follow more less

PUBLISH YOUR CONTENT ON JD SUPRA

• ✔ Increased readership
• ✔ Actionable analytics
• ✔ Ongoing writing guidance Join more than 70,000 authors publishing their insights on JD Supra

Start Publishing »

Published In:

Centers for Medicare & Medicaid Services (CMS) + Follow Digital Health + Follow Food and Drug Administration (FDA) + Follow Health Information Technologies + Follow Healthcare + Follow Innovation + Follow Medical Devices + Follow Regulatory Oversight + Follow Regulatory Requirements + Follow Technology Sector + Follow Telehealth + Follow Administrative Agency + Follow Government Contracting + Follow Health + Follow Science, Computers & Technology + Follow more less

Venable LLP on:

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra: Sign Up Log in ** By using the service, you signify your acceptance of JD Supra's Privacy Policy.* - hide - hide